The paradigm shift in the treatment of type 1 diabetes mellitus (T1DM) from regimens based on extrapolation of historical data to algorithm-controlled insulin delivery systems based on real-time continuous glucose monitoring (CGM) has changed the clinical landscape by providing new therapeutic targets, as well as a leap in the proportion of people with T1DM safely achieving these goals. This evidence concerns the gene INS and diabetes mellitus.